[The effect of antidiabetic treatment on the bone of patients with type 2 diabetes].
Despite a normal or higher bone mass, type 2 diabetes is associated with a higher risk of osteoporotic fractures. Besides a higher falls frequency the lower quality of diabetics bone plays the crucial role in this case. One of the factors affecting their fracture risk is a choice of antidiabetic treatment. So far, professional societies have warned before the thiazolidinediones use only, but gliflozines can be harmful for bone too. Metformin, sulfonylureas, GLP-1 agonists and DPP-4 inhibitors belong to the drugs without a negative effect on the fracture risk. The increased frequency of bone fractures in diabetics treated with insulin lies more in the fact that these patients suffer from diabetes longer, have more diabetic complications and are at a higher risk of hypoglycemia, which is associated with a higher frequency of falls. In individuals with a high fracture risk antidiabetic drugs without a negative effect on bones should be recommended.


BACKGROUND
DPP-4 inhibitors - gliflozines - GLP-1 agonists - insulin - metformin - osteoporosis - sulfonylureas - thiazolidinediones - type 2 diabetes mellitus.
David
D
Karásek
D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D058866:Osteoporotic Fractures / Q000209:etiology* / Q000517:prevention & control*
D007004:Hypoglycemic Agents